[ad_1]
Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines.
MLTX down about 2% premarket.
“Lacking near-term catalysts, MLTX is expected to lay dormant, especially with HS volume slowdown. Wolfe sees downside risk from potentially overpromised timeline.
Over the next 2–3 quarters, Wolfe expects MLTX to trade in tandem with the XBI index (I.E. between $40 and $55 assuming no biotech bull run),” Wolfe mentioned in an announcement.
The analysis agency mentioned that it could be fallacious on this downgrade ought to an M&A happen over the subsequent ~12-18 months, but it surely believes MLTX now not matches the mould of ‘pharma M&A goal’.
“A better time to re-evaluate MLTX would be ~Q1/Q2 2025 if MLTX meets the enrollment target (likely no rewards for meeting this timeline but could be penalized for delays). Though Wolfe is bullish on product POS, it finds the near term setup less favorable,” it provides.
The firm has a Hold suggestion in response to SA quant system, and the inventory has fallen about 17.6% YTD.
[ad_2]
Source: Seekingalpha